Institutional profile: University of Florida Health Personalized Medicine Program

被引：63

作者：

Cavallari, Larisa H. ^{[1
,2
,3
]}

Weitzel, Kristin W. ^{[1
,2
,3
]}

Elsey, Amanda R. ^{[1
,3
]}

Liu, Xinyue ^{[4
]}

Mosley, Scott A. ^{[1
,2
]}

Smith, Donald M. ^{[1
,2
]}

Staley, Benjamin J. ^{[4
,5
]}

Winterstein, Almut G.

Mathews, Carol A. ^{[6
]}

Franchi, Francesco ^{[7
]}

Rollini, Fabiana ^{[7
]}

Angiolillo, Dominick J. ^{[7
]}

Starostik, Petr ^{[8
]}

Clare-Salzler, Michael J. ^{[3
,8
]}

Nelson, David R. ^{[2
,9
]}

Johnson, Julie A. ^{[1
,2
,3
,9
]}

机构：

[1] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32610 USA

[2] Univ Florida, Ctr Pharmacogen, Gainesville, FL 32610 USA

[3] Univ Florida, Clin & Translat Sci Inst, Gainesville, FL 32610 USA

[4] Univ Florida, Coll Pharm, Dept Pharmaceut Outcomes & Policy, Gainesville, FL 32610 USA

[5] Univ Florida, Dept Pharm, Hlth Shands Hosp, Gainesville, FL 32608 USA

[6] Univ Florida, Coll Med, Dept Psychiat, Gainesville, FL 32610 USA

[7] Univ Florida, Coll Med, Dept Med, Jacksonville, FL 32209 USA

[8] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA

[9] Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA

来源：

PHARMACOGENOMICS | 2017年 / 18卷 / 05期

关键词：

clopidogrel; education; genotype; implementation; opioids; PEG-interferon; pharmacogenetics; proton pump inhibitors; selective serotonin uptake inhibitors; thiopurines; CLINICAL IMPLEMENTATION; PHARMACOGENETICS; GENOTYPE; GUIDELINES; THERAPY;

D O I：

10.2217/pgs-2017-0028

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The University of Florida (UF) Health Personalized Medicine Program launched in 2012 with CYP2C19 genotyping for clopidogrel response at UF Health Shands Hospital. We have since expanded CYP2C19 genotyping to UF Health Jacksonville and established the infrastructure at UF Health to support clinical implementation for five additional gene-drug pairs: TPMT-thiopurines, IFNL3 (IL28B)-PEG IFN-alpha-based regimens, CYP2D6-opioids, CYP2D6/CYP2C19-antidepressants and CYP2C19-proton pump inhibitors. We are contributing to the evidence based on outcomes with genotype-guided therapy through pragmatic studies of our clinical implementations. In addition, we have developed a broad array of educational programs for providers, trainees and students that incorporate personal genotype evaluation to enhance participant learning.

引用

页码：421 / 426

页数：6

共 13 条

[1]

Cavallari LH, 2016, CIRCULATION, V134, pE711

[2]

Cavallari LH, 2015, CIRCULATION

[3]

Crews KR, CLIN PHARM THER

[4] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors [J].

Hicks, J. K. ;

Bishop, J. R. ;

Sangkuhl, K. ;

Mueller, D. J. ;

Ji, Y. ;

Leckband, S. G. ;

Leeder, J. S. ;

Graham, R. L. ;

Chiulli, D. L. ;

LLerena, A. ;

Skaar, T. C. ;

Scott, S. A. ;

Stingl, J. C. ;

Klein, T. E. ;

Caudle, K. E. ;

Gaedigk, A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (02) :127-134

[5] Implementing Personalized Medicine: Development of a Cost-Effective Customized Pharmacogenetics Genotyping Array [J].

Johnson, J. A. ;

Burkley, B. M. ;

Langaee, T. Y. ;

Clare-Salzler, M. J. ;

Klein, T. E. ;

Altman, R. B. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (04) :437-439

[6]

Johnson JA, 2013, PHARMACOGENOMICS, V14, P723, DOI [10.2217/PGS.13.59, 10.2217/pgs.13.59]

[7] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-α-Based Regimens [J].

Muir, A. J. ;

Gong, L. ;

Johnson, S. G. ;

Lee, M. T. M. ;

Williams, M. S. ;

Klein, T. E. ;

Caudle, K. E. ;

Nelson, D. R. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (02) :141-146

[8] Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing [J].

Relling, M. V. ;

Gardner, E. E. ;

Sandborn, W. J. ;

Schmiegelow, K. ;

Pui, C-H ;

Yee, S. W. ;

Stein, C. M. ;

Carrillo, M. ;

Evans, W. E. ;

Klein, T. E. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (03) :387-391

[9] Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype [J].

Sugimoto, Mitsushige ;

Furuta, Takahisa .

WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (21) :6400-6411

[10] Effects of CYP2C19 Loss-of-Function Variants on the Eradication of H. pylori Infection in Patients Treated with Proton Pump Inhibitor-Based Triple Therapy Regimens: A Meta-Analysis of Randomized Clinical Trials [J].

Tang, Hui-Lin ;

Li, Yan ;

Hu, Yong-Fang ;

Xie, Hong-Guang ;

Zhai, Suo-Di .

PLOS ONE, 2013, 8 (04)

← 1 2 →